ASF Standards · Ambulatory Clinic · Standard 18

Standard 18 — Allergy & Immunotherapy

3 criteria · 3 non-negotiable · 0 core · Version 3.0

Criteria in this standard

18.1 — Post-Injection Observation Time Is Enforced, Not Assumed
18.2 — Dose Escalation Follows a Defined, Individualized Schedule
18.3 — Extract Preparation and Labeling Prevents Vial Mix-Up

18.1

Post-Injection Observation Time Is Enforced, Not Assumed

Non-Negotiable

Every patient receiving an allergen immunotherapy injection is observed on-site for the minimum required period afterward, with this actually enforced — not left to the patient's own judgement about whether they feel well enough to leave early.

In plain terms: After every allergy shot, the patient stays in the clinic for the full observation period — the clinic enforces it, and does not let the patient decide to leave early.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

Allergen immunotherapy injects the substance the patient is allergic to. Systemic reactions — including anaphylaxis — occur in about 1 in 1,000 injections, and most begin within 30 minutes. A patient who leaves at 10 minutes and reacts in the car park has no adrenaline and no one to give it. The 30-minute observation (longer for high-risk patients) is not advice; it is a requirement. Enforcement means: the patient signs in at injection time, is not discharged until the period is complete and a staff member has checked them, and a patient who insists on leaving early signs an against-advice form and is reconsidered for continued treatment.

What good looks like

The minimum observation period is genuinely enforced for every patient.
Departure time is recorded and verifiably matches or exceeds the required period.
A specific, known process exists for extending observation when symptoms develop.

Common failure modes

Patients are permitted to leave early based on how they feel.
No record exists comparing injection time against actual departure time.
Staff are uncertain what happens if symptoms develop during observation.

Worked example

In practice

An allergy clinic giving 80 immunotherapy injections a week.

BeforePatients were told to wait 30 minutes. Many left after 10 to get to work. No one checked. A patient developed anaphylaxis in the car 15 minutes after leaving; he survived because a passing pharmacist had adrenaline. The clinic had no enforcement mechanism.

ActionAn observation protocol was implemented: injection time recorded on a wristband; the patient sits in a designated area visible from the nurses' station; discharge only after 30 minutes (45 for high-risk) and a nurse check of symptoms and vital signs, documented; a patient who insists on leaving early signs a form and their case is reviewed by the allergist for suitability to continue. Adrenaline and the anaphylaxis kit are at the observation area.

AfterThe Monitor observed the waiting area with wristbands, reviewed 30 injection records with documented 30-minute checks, and two early-leaver forms with follow-up review. Verified.

If you are starting from zero — do this first

Watch three patients after their injection. How long do they actually stay?
Introduce a time-stamped wristband and a documented discharge check.
Put the anaphylaxis kit in the observation area.
Write the early-leaver procedure.

The most common mistake: Advising a 30-minute wait and treating it as the patient's choice — a reaction in the car park is the clinic's failure.

Self-assessment questions

1. Is the minimum observation period actually enforced for every patient, not left to the patient's own judgement? — Genuinely enforced, not a recommendation the patient can opt out of by feeling ready to leave.
Evidence: Observation enforcement protocol

2. Is the patient's departure time actually recorded and compared against injection time? — A real, checkable record, not an assumption the full period was observed.
Evidence: Departure time tracking record

3. Is there a specific process for extending observation if symptoms develop during the standard window? — A defined, known extension process, not uncertainty about what happens if something develops.
Evidence: Extended observation protocol

Common reasons for a PARTIAL answer

Observation is enforced during busy periods when staff are actively monitoring the waiting area, but less consistently when the area is quiet. — The requirement doesn't depend on how busy the facility happens to be at the time.
Departure time is recorded but not actually compared against injection time to verify compliance. — A recorded time that's never checked against the requirement doesn't provide real verification.
Extension happens for obvious reactions but the threshold for what warrants extension isn't clearly defined.

Implementation plan

When	What
Week 1	Review current observation practice for genuine enforcement, not patient-judgement-based departure.
Week 2	Establish a recorded departure time process, compared against injection time.
Week 3	Define and brief staff on a specific extended observation protocol.
Ongoing	Audit departure time records against the minimum requirement periodically.

How the Monitor verifies this

Method	What	Detail
OBSERVE	Observation enforcement check	Observes actual practice to confirm patients are genuinely held for the minimum period, not permitted to leave early.
DOCUMENT	Departure time record review	Reviews records comparing injection time against actual departure time for a sample of patients.
ASK	Extended observation interview	Asks staff what happens specifically if symptoms develop during the standard observation window.

Supervisor tips

Ask to see actual departure time records compared against injection times for real patients. — Specific, dated records are the only real evidence the requirement is genuinely enforced.
Observe the waiting area during a quiet period specifically. — Enforcement is most likely to relax exactly when the area feels calm and unhurried.

Evidence base

[83] Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-55 — establishes a minimum post-injection observation period as a core safety requirement of allergen immunotherapy administration.

Train your team: AMB-18 · Allergy & Immunotherapy on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

18.2

Dose Escalation Follows a Defined, Individualized Schedule

Non-Negotiable

Immunotherapy dose escalation follows a defined schedule, individually adjusted for missed doses, prior reactions, and known risk factors — not advanced automatically according to a fixed calendar regardless of what actually happened at the previous visit.

In plain terms: Immunotherapy doses increase on a written schedule adjusted for each patient — missed doses, previous reactions, high-risk factors — not advanced automatically by the calendar.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

The build-up phase increases the allergen dose step by step to reach maintenance. A patient who missed two weeks and then receives the next scheduled increase has jumped several steps and may react. A patient who had a large local reaction last time needs the dose held or reduced, not increased. A patient with asthma, on beta-blockers, or during pollen season, is at higher risk and needs a slower schedule. The clinic must have a written schedule per extract, written rules for adjustment, and a check before every injection: what was the last dose, what was the reaction, how long ago, what has changed?

What good looks like

Missed doses trigger a specific, defined adjustment to the escalation schedule.
A prior reaction genuinely changes subsequent dose decisions.
Dose and escalation status are actively verified against the record before each injection.

Common failure modes

Doses advance automatically according to a calendar regardless of missed visits.
Prior reactions don't change subsequent dosing decisions.
Dose is assumed from time elapsed rather than verified against the actual record.

Worked example

In practice

An allergy clinic with 120 patients in immunotherapy build-up.

BeforeThe schedule was printed on a card; the nurse gave the next dose on the card regardless of interval or prior reaction. A patient who had missed four weeks received the next dose and developed anaphylaxis. Another with asthma exacerbation was not asked about it and reacted.

ActionDose adjustment rules were written per national guidance: missed doses → step back by a defined number of steps depending on interval; large local reaction → repeat dose; systemic reaction → reduce and allergist review; asthma unstable, beta-blocker started, or peak pollen → hold and review. A pre-injection checklist is completed every visit: last dose date, last reaction, current symptoms, medication changes, peak flow for asthmatics. The nurse cannot give a dose that deviates from the rules without allergist sign-off.

AfterThe Monitor reviewed 30 injection records with completed pre-injection checklists and rule-based adjustments; five showed step-backs after missed doses. Systemic reactions in six months: 0. Verified.

If you are starting from zero — do this first

Ask your nurse what happens if a patient has missed three weeks. If the answer is 'give the next dose,' that is the gap.
Write adjustment rules for missed doses, reactions, and risk factors.
Add a pre-injection checklist to every visit.
Require allergist sign-off for any deviation.

The most common mistake: Following the card schedule regardless of what has happened since the last injection.

Self-assessment questions

1. Is dose escalation adjusted for missed doses, not advanced automatically as if the prior visit occurred on schedule? — A specific, defined adjustment rule for missed doses, not automatic progression.
Evidence: Missed-dose adjustment protocol

2. Is dose escalation adjusted based on any reaction at the prior dose, not proceeding regardless? — Genuine responsiveness to prior reaction history for this specific patient.
Evidence: Prior-reaction dose adjustment record

3. Is the current dose and escalation status verified before each injection, not assumed from the calendar? — An active check against the patient's actual record, not assumed from how much time has passed.
Evidence: Pre-injection dose verification record

Common reasons for a PARTIAL answer

Missed-dose adjustment happens for longer gaps but not shorter, still-relevant delays. — Even a shorter-than-expected gap can carry meaningful risk depending on the specific interval.
Prior reactions are noted in the record but don't consistently change the next dose decision. — A noted reaction that doesn't influence the subsequent decision doesn't provide the protection this criterion is meant to ensure.
Verification happens for new or unusual cases but becomes less rigorous for routine, long-established patients.

Implementation plan

When	What
Week 1	Review current escalation practice for genuine adjustment based on missed doses and prior reactions.
Week 2	Establish or reinforce a specific, defined missed-dose adjustment rule.
Week 3	Build active pre-injection verification into the standard workflow for every patient.
Ongoing	Audit escalation decisions against missed-dose and prior-reaction adjustment rules.

How the Monitor verifies this

Method	What	Detail
DOCUMENT	Missed-dose adjustment review	Reviews records for evidence that missed doses trigger a defined adjustment, not automatic progression.
DOCUMENT	Prior-reaction adjustment review	Reviews whether a prior reaction genuinely changes the subsequent dose decision.
OBSERVE	Pre-injection verification observation	Observes whether dose and escalation status are actively verified against the patient's record before each injection.

Supervisor tips

Ask for a real example of a missed dose and how the schedule was adjusted. — A real example reveals whether adjustment is genuine practice, not just a stated policy.
Ask staff to verify a specific patient's current dose status directly from the record, not from memory. — This reveals whether verification is genuinely active, not assumed from familiarity with a long-standing patient.

Evidence base

[84] Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-55 — establishes dose adjustment for missed doses and prior reactions as a core safety requirement of immunotherapy dose escalation.

Train your team: AMB-18 · Allergy & Immunotherapy on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

18.3

Extract Preparation and Labeling Prevents Vial Mix-Up

Non-Negotiable

Allergen extract preparation, dilution, and labeling follows a defined, verified process specifically designed to prevent vial mix-up between patients — with a genuine, independent check before administration confirming the correct vial for the correct patient.

In plain terms: Allergen extracts are prepared, diluted, and labelled by a defined process that prevents one patient's vial being used for another — with an independent check before every injection.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

Each patient's extract is unique — their allergens, their concentration. Giving patient A's maintenance-strength extract to patient B, who is on a low build-up dose of a different allergen, can cause fatal anaphylaxis. Vials look identical. Names are similar. Storage is a shared fridge. Prevention means: patient-specific labelling with two identifiers and the concentration; a defined dilution procedure with a second-person check; storage segregated by patient; and, before every injection, an independent check of the vial against the patient's identity and schedule — read aloud, by someone other than the person drawing up.

What good looks like

A specific, defined process prevents vial mix-up in preparation and labeling.
A genuine, independent vial-to-patient check happens before every administration.
Labeling is specifically checked, not just present.

Common failure modes

No specific mix-up prevention process exists beyond general care.
Vial verification isn't genuinely independent or is folded loosely into general patient identification.
Labels exist but aren't specifically checked before administration.

Worked example

In practice

An allergy clinic preparing extracts for 150 patients in a shared refrigerator.

BeforeVials were labelled with surname only. Dilutions were prepared by one nurse without a check. The fridge held all vials alphabetically. Two patients named Petrov had vials adjacent; the wrong one was used, causing a systemic reaction. No independent pre-injection check was performed.

ActionLabelling was standardised: full name, date of birth, allergen mix, concentration, date prepared, expiry. Dilutions are prepared by one nurse and checked by a second, both signing. Each patient's vials are stored in a labelled individual box. Before injection, a second staff member reads the vial label against the patient's wristband and schedule aloud, and both sign. Same-name patients are flagged in the system.

AfterThe Monitor observed two injections with independent vial checks, inspected the fridge with individual patient boxes, and reviewed 30 records with double signatures. Verified.

If you are starting from zero — do this first

Open your extract fridge. Are vials labelled with two identifiers? Are same-name patients adjacent?
Standardise labels and store each patient's vials in a labelled box.
Require a second-person check on every dilution.
Require an independent vial-to-patient check before every injection.

The most common mistake: Labelling vials with surname only — two Petrovs in one fridge is a disaster waiting.

Self-assessment questions

1. Is there a defined process for preparing and labeling extract vials that specifically prevents mix-up between patients? — A specific, designed process, not general care assumed to be sufficient.
Evidence: Extract preparation and labeling protocol

2. Is there a genuine, independent check confirming the correct vial for the correct patient before administration, distinct from general patient identification? — A specific vial-to-patient check, not folded into or assumed covered by general identification.
Evidence: Vial verification record

3. Are vials specifically labeled with concentration and patient identity in a way that's checked, not just present? — Genuinely checked labeling, not assumed correct because a label exists.
Evidence: N/A — tested directly

Common reasons for a PARTIAL answer

Verification is rigorous when a single patient is being seen but becomes less consistent during busy periods with multiple patients. — Mix-up risk is highest exactly when multiple vials for different patients are present simultaneously.
Labeling includes patient name but concentration isn't consistently double-checked. — Correct patient with incorrect concentration still represents a real, distinct risk.
The check happens but isn't genuinely independent — the same person prepares and verifies.

Implementation plan

When	What
Week 1	Review current extract preparation and labeling practice for mix-up prevention specificity.
Week 2	Establish a genuine, independent vial-to-patient verification step before every administration.
Week 3	Reinforce labeling practice to include both patient identity and concentration, both checked.
Ongoing	Observe verification practice periodically, particularly during busy periods with multiple patients.

How the Monitor verifies this

Method	What	Detail
DOCUMENT	Preparation and labeling protocol review	Reviews the defined process for extract preparation and labeling specific to mix-up prevention.
OBSERVE	Vial verification observation	Observes an actual pre-administration check for genuine, independent vial-to-patient verification.
ASK	Labeling practice interview	Asks staff to describe how they confirm vial concentration and patient identity match before administering.

Supervisor tips

Observe during a period when multiple patients are being seen for injections. — This is exactly when mix-up risk is highest and verification discipline most likely to be tested.
Ask whether the same person both prepares and verifies, or whether this is genuinely independent. — Genuine independence between preparation and verification is what distinguishes a real check from a formality.

Evidence base

[85] Correct extract and concentration verification, distinct from and in addition to general patient identification, is established practice for preventing vial mix-up in allergen immunotherapy administration.

Train your team: AMB-18 · Allergy & Immunotherapy on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

← Ambulatory Clinic Standards — all standards
Self-assess against these criteria →
← Standard 17 — Dermatology
Standard 19 — Plastic & Cosmetic Surgery →